180
Participants
Start Date
October 31, 2015
Primary Completion Date
September 30, 2022
Study Completion Date
September 30, 2022
PegIFN alfa-2a
180 μg/ 0.5 ml ,hypodermic injection once a week
Wuhan Seventh People's Hospital, Wuhan
Changzhou Third People's Hospital, Changzhou
First Affiliated Hospital of Zhejiang University, Hangzhou
People's Hospital of Jiangsu Province, Nanjing
Nantong Third People's Hospital, Nantong
Suzhou Fifth People's Hospital, Suzhou
The First Affiliated Hospital of Soochow University, Suzhou
Taicang People's Hospital, Taicang
Wuxi Infectious Disease Hospital, Wuxi
Affiliated Hospital of Xuzhou Medical College, Xuzhou
Shandong Provincial Hospital, Jinan
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Changhai Hospital Affiliated to Second Military Medical University, Shanghai
Huashan Hospital Affiliated to Fudan University, Shanghai
Ruijin Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Public Health Clinical Center, Shanghai
Shanghai Third People's Hospital, Shanghai
Shuguang Hospital Affiliate to Shanghai University of Traditional Chinese Medicine, Shanghai
The Infectious Disease Hospital of Shanghai Huangpu Distric, Shanghai
Huashan Hospital
OTHER